Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

NCT02888236 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT02888236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02888236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
Lead sponsor
LEO Pharma
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2016
Completion date
July 6, 2017
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis vulgaris